JP7566753B2 - 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料 - Google Patents

転写因子ｅｂポリペプチドレベルを増加させるための方法および材料 Download PDF

Info

Publication number
JP7566753B2
JP7566753B2 JP2021538743A JP2021538743A JP7566753B2 JP 7566753 B2 JP7566753 B2 JP 7566753B2 JP 2021538743 A JP2021538743 A JP 2021538743A JP 2021538743 A JP2021538743 A JP 2021538743A JP 7566753 B2 JP7566753 B2 JP 7566753B2
Authority
JP
Japan
Prior art keywords
alkyl
disease
compound
independently selected
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021538743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516631A (ja
JP2022516631A5 (https=
Inventor
チェン，ベイベイ
フィンケル，トーレン
リウ，ユアン
Original Assignee
ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2022516631A publication Critical patent/JP2022516631A/ja
Publication of JP2022516631A5 publication Critical patent/JP2022516631A5/ja
Application granted granted Critical
Publication of JP7566753B2 publication Critical patent/JP7566753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2021538743A 2019-01-03 2020-01-03 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料 Active JP7566753B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788049P 2019-01-03 2019-01-03
US62/788,049 2019-01-03
US201962879374P 2019-07-26 2019-07-26
US62/879,374 2019-07-26
PCT/US2020/012268 WO2020142748A1 (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Publications (3)

Publication Number Publication Date
JP2022516631A JP2022516631A (ja) 2022-03-01
JP2022516631A5 JP2022516631A5 (https=) 2023-01-06
JP7566753B2 true JP7566753B2 (ja) 2024-10-15

Family

ID=71406977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538743A Active JP7566753B2 (ja) 2019-01-03 2020-01-03 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料

Country Status (12)

Country Link
US (2) US12286442B2 (https=)
EP (1) EP3906033A4 (https=)
JP (1) JP7566753B2 (https=)
KR (1) KR102904932B1 (https=)
CN (1) CN113316453B (https=)
AU (1) AU2020204717B2 (https=)
BR (1) BR112021012950A2 (https=)
CA (1) CA3123902A1 (https=)
IL (1) IL284403A (https=)
MX (1) MX2021008152A (https=)
SG (1) SG11202105685TA (https=)
WO (1) WO2020142748A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CN121941701A (zh) * 2023-07-28 2026-04-28 特兰埃克斯公司 用于治疗溶酶体病症的突变tfeb
CN119818678A (zh) * 2024-12-24 2025-04-15 广州医科大学附属妇女儿童医疗中心 Tfeb在制备变应性鼻炎的药物中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
JP2004509113A (ja) 2000-09-15 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
JP2006522119A (ja) 2003-03-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なキナゾリン
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2011135351A1 (en) 2010-04-30 2011-11-03 Karus Therapeutics Limited Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases
JP2011529932A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
JP2011529931A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用
JP2013525405A (ja) 2010-04-29 2013-06-20 グラクソ グループ リミテッド Ｓｙｋ阻害薬としての７−（１ｈ−ピラゾール−４−イル）−１，６−ナフチリジン化合物
JP2017536363A (ja) 2014-11-19 2017-12-07 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症治療のための組成物及び方法
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7198926B2 (en) * 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
CN104812387A (zh) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509113A (ja) 2000-09-15 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
JP2006522119A (ja) 2003-03-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なキナゾリン
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP2011529931A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用
JP2011529932A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
JP2013525405A (ja) 2010-04-29 2013-06-20 グラクソ グループ リミテッド Ｓｙｋ阻害薬としての７−（１ｈ−ピラゾール−４−イル）−１，６−ナフチリジン化合物
WO2011135351A1 (en) 2010-04-30 2011-11-03 Karus Therapeutics Limited Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases
JP2017536363A (ja) 2014-11-19 2017-12-07 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症治療のための組成物及び方法
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2015年，6(3)，287-291
Bioorganic & Medicinal Chemistry Letters ，2009年，19(6)，1802-1806
Bioorganic & Medicinal Chemistry Letters ，2009年，19(6)，1807-1810
Nature Communications ，2017年，8，2270
PubChem，https://pubchem.ncbi.nlm.nih.gov/compound/10425575#section=2D-Structure，Identifier: CID 2244 (Create:2006-10-25)
REGISTRY（STN）[online]，2012.07.05 [検索日 2023.11.16] CAS登録番号 1381678-54-1 ほか１件

Also Published As

Publication number Publication date
KR20210111787A (ko) 2021-09-13
BR112021012950A2 (pt) 2021-09-14
US12286442B2 (en) 2025-04-29
AU2020204717A1 (en) 2021-06-10
CA3123902A1 (en) 2020-07-09
JP2022516631A (ja) 2022-03-01
SG11202105685TA (en) 2021-06-29
CN113316453A (zh) 2021-08-27
US20250382309A1 (en) 2025-12-18
EP3906033A1 (en) 2021-11-10
US20220112218A1 (en) 2022-04-14
AU2020204717B2 (en) 2025-01-16
IL284403A (en) 2021-08-31
MX2021008152A (es) 2021-10-13
EP3906033A4 (en) 2022-11-09
CN113316453B (zh) 2025-12-23
KR102904932B1 (ko) 2025-12-26
WO2020142748A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP7566753B2 (ja) 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
DE60316542T2 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
EP3557998B1 (en) Compouns, compositions and methods of use
EP1339714B1 (de) Neue sulfonamid-substituierte pyrazolopyridinderivate
EP4192454B1 (en) Azabicyclo-amino-triazine compounds for modulating splicing for the treatment of neurological diseases
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN110023311A (zh) 2-取代的氨基-萘并[1,2-d]咪唑-5-酮类化合物或其药学上可接受的盐
JP2023544653A (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
EP2888252B1 (en) Benzofurazan anti-amyloid compounds and methods
WO2022060943A1 (en) Compositions for modulating splicing
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
CA3253274A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT
US5900426A (en) Benzothiazole derivatives
CA3090439A1 (en) Compound having bet inhibitory activity and preparation method and use therefor
RU2838857C2 (ru) Способы и материалы для повышения уровней полипептида фактора транскрипции eb
WO2023060173A1 (en) Compounds, compositions and methods of use
US20020132852A1 (en) Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
CN115785094B (zh) 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途
CN102408395B (zh) 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
CN102796075B (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
WO2015090224A1 (zh) 新型哌啶氨甲酰类化合物、制备方法及其用途
AU2001249957A1 (en) Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-Ribose) glycohydrolase, and methods for their use

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7566753

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150